Pharma Mar SA

Overview

Pharma Mar SA (Pharma Mar) discovers, develops and markets marine-derived drugs to treat cancer. The company’s marketed products include Yondelis (trabectedin) an antitumor agent indicated for the treatment of soft tissue sarcoma and relapsed ovarian cancer in combination with doxorubicin HCl liposome injection; Aplidin (plitidepsin), an anticancer agent for the treatment of multiple myeloma; and Zepzelca (lurbinectedin) for small cell lung cancer. Pharma Mar offers in vitro diagnostic products used for detection of virus and bacteria in respiratory infections and human papilloma virus genotypes, among others. Pharma Mar also offers kits used for diagnosis of SARS-CoV-2, influenza A and B and respiratory syncytial virus. Its development pipeline includes PM184 and PM14 for solid tumors, among others. It also develops RNAi candidates for the treatment of retina diseases. The company has subsidiaries in Germany, Italy, France, Switzerland, the UK and the US, among others. Pharma Mar is headquartered in Madrid, Spain.
Key Stats
Address
Avda. De Los Reyes, 1, Pol. Ind. La Mina, Colmenar Viejo, Madrid
Headquarters

Spain

Contact

34 918 466000

No of Employees

451

Industry

Pharmaceuticals and Healthcare

Ticker Symbol & Exchange​

PHM [MCE]

Revenue (2020)

$308 m

220.6% (2020 vs 2019)
Net Income (2020)

$156 m

1324.5% (2020 vs 2019)
Net Profit Margin

51 %

483.5% (2020 vs 2019)
Market Cap *

$1,494 m

EPS *

$7.5

  *Note: Ratios based on the share price as of 6-October-2021, in absolute numbers and US$.

Peer Comparison

Key Parameters Pharma Mar SACTI BioPharma Corp
Key Information
Headquarters Spain United States of America
Headquarter City Colmenar Viejo Seattle
Headquarter State/Province Madrid Washington
No. of Employees 451 22
Entity Type Public Public

Products & Services

Pharma Mar is a biopharmaceutical company. The company's key products include the following:

Products
  • Yondelis – Soft Tissue Sarcoma and Ovarian Cancer
  • Zepzelca (Lurbinectedin) - Small Cell Lung Cancer and Solid Tumors
  • Aplidin - Multiple Myeloma
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
Brands
  • Yondelis
  • Aplidin
  • Zepzelca
  • Rutrum Elit
  • Rutrum Elit
  • Rutrum Elit
  • Rutrum Elit
Key Financial Charts
Sales Growth
Operating Margin
Net Income Growth
EPS (Earnings per Share)
Debt to Equity Ratio
Return on Assets

Employees

Name Position Board Since Age Biography
Jose Maria Fernandez Sousa-Faro, Ph.D. Chief Executive Officer; Chairman; President Executive Board - - Mr. Jose Maria Fernandez Sousa-Faro is the Chairman of the company. Prior to this, he was the member of the...
Maria Luisa de Francia Caballero Chief Financial Officer Senior Management - - Ms. Maria Luisa de Francia Caballero has been the Chief Financial Officer of the company. Prior to this, she held...
Non Dignissim Eros Proin vel Convallis 2015 XX In vitae nisi ut tortor rutrum suscipit vel vitae ligula. Mauris sed tellus non augue ultricies ultricies. Aliquam vitae urna congue.
Non Dignissim Eros Proin vel Convallis 2015 XX In vitae nisi ut tortor rutrum suscipit vel vitae ligula. Mauris sed tellus non augue ultricies ultricies. Aliquam vitae urna congue.

History

Year Event Description
2021 Contracts/Agreements In March, the company entered into licensing agreement with Adium Pharma SA to commercialize Zepzelca…
2021 Regulatory Approval In September, the company's Zepzelca (lurbinectedin) received approval from the United Arab Emirates Ministry of…
2020 Contracts/Agreements In November, the company entered into licensing agreement with STADA MENA DWC-LLC to commercialize Yondelis…
2020 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam
2020 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam
2020 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam

Locations


Pharma Mar GmbH

Address

Uhlandstrasse 14, Berlin
Germany

Telephone

49 30 31991820

Zelnova Zeltia SA

Address

Industrial Estate Torneiron s / n, Porrino
Spain

Telephone

34 98 6344920

Website

www.zelnova.com
Pharma Mar SARL

Address

6 Rue de l'est, Boulogne Billancourt, Paris
France

Telephone

33 180 730320

Pharma Mar USA Inc

Address

Suite 1000, 230 Park Ave., New York City
United States of America

Telephone

1 212 3098737

Genomica SAU

Address

Alvento Business Park Building, B. Calle Vía de los Poblados 1 - 1st Floor, Madrid
Spain

Telephone

34 91 6748990

Website

www.genomica.com
Pharma Mar Srl

Address

Via Giorgio Stephenson, 29, Milan
Italy

Telephone

39 249 752069

Website

www.pharmamar.com
Sylentis SAU

Address

Calle de Santiago Grisolia, 2, Parque Cientifico, Madrid
Spain

Telephone

34 91 8047667

Website

www.sylentis.com
Noscira S.A.

Address

Avenida de la Industria 52, Tres Cantos, Madrid 28760
Spain

Telephone

34 91 806 11 30

Website

http://www.noscira.com

Deals

Number of Deals
Deal Value (US$ m)

Latest Deals

Announced Date Headline Deal Type Acquirers / Investors / Surviving Entity Issuer / partner / Target
23 Dec 2020 R-Pharm Enters into Licensing Agreement with Pharma Mar Licensing Agreement R-Pharm Pharma Mar SA
17 Nov 2020 STADA MENA DWC Enters into Licensing Agreement with PharmaMar Licensing Agreement STADA MENA DWC-LLC Pharma Mar SA
10 Aug 2020 Onko Ilac San ve Tic Enters into Licensing Agreement with PharmaMar for Yondelis Licensing Agreement Onko Ilac San ve Tic AS Pharma Mar SA
27 Jul 2020 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit
09 Jun 2020 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit
19 May 2020 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit

Jobs Overview

9

Active Jobs

11

Posted

5

Closed

Job Trends

Latest Jobs

Job title Company Country
Clinical Project Manager October 4, 2021 Pharma Mar SA Spain
Clinical Research Associate (CRA) October 4, 2021 Pharma Mar SA Spain
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar